Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion completes enrollment for Aegis study
The open-label study, which was authorized by the Japan’s Pharmaceutical and Medical Device Administration (PMDA), over-enrolled a total of 29 patients. The patients will be treated with Soliris
The open-label study, which was authorized by the Japan’s Pharmaceutical and Medical Device Administration (PMDA), over-enrolled a total of 29 patients. The patients will be treated with Soliris
The newly issued patent includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867. The preclinical development for PX-867 has focused on cardiovascular disease.
Michael Kauffman, CEO of Epix, said: “While PRX-00023 continued to show a highly desirable safety and tolerability profile, we are disappointed in the overall results observed in our
The lower doses are believed to be more physiologically relevant. The data showed that the rate of absorption of B12 administered with eligen increased significantly 26 to 34
The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging
In collaboration with doctors from University of California, San Diego (UCSD) School of Medicine, Bennu plans to initiate a Phase IIa clinical study of delayed release cysteamine (DR
On January 16, 2008, Medtronic sent a letter to inform clinicians worldwide of an increase in the rate of reported inflammatory mass cases in patients who have received
As part of the transaction, Emergent acquired Avanir’s lead candidate (AVP-21D9) along with several additional anthrax antibodies. In addition, Emergent also received a limited exclusive license to use
Solagran’s manufacturing partner Galenopharm is now free to commence production of Ropren for sale throughout Russia. Solagran is hopeful that initial production volumes will be sufficient to meet
Under terms of the agreement, the companies will evenly divide the value of the joint venture. Abbott receives rights to the oncology treatment, Lupron, including the commercial organization